Updates on campus events, policies, construction and more.


Information for Our Community

Whether you are part of our community or are interested in joining us, we welcome you to Washington University School of Medicine.


Visit the News Hub

Brain tumors caused by normal neuron activity in mice predisposed to such tumors

Light triggers formation, feeds growth of optic nerve tumors

by Tamara BhandariMay 26, 2021

Getty Images

Seeing, hearing, thinking, daydreaming — doing anything at all, in fact — activates neurons in the brain. But for people predisposed to developing brain tumors, the ordinary buzzing of their brains could be a problem. A study by researchers at Washington University School of Medicine in St. Louis and Stanford University School of Medicine shows that the normal day-to-day activity of neurons can drive the formation and growth of brain tumors.

The researchers studied mice genetically prone to developing tumors of their optic nerves, the bundle of neurons that carries visual signals from the eyes to the brain. The mice served as a model for children with the genetic condition neurofibromatosis type 1 (NF1). About one in six children with NF1 develops low-grade optic nerve tumors by age 7. In this study, mice with Nf1 mutations raised under normal lighting developed tumors; those kept in the dark during a critical period of development did not.

The findings, published May 26 in the journal Nature, suggest that neuronal activity plays an underappreciated role in nervous system cancers. The research opens up new avenues to preventing brain tumors in children at high risk for them.

“Optic gliomas are very common in children with NF1, and they can cause vision loss,” said co-senior author David H. Gutmann, MD, PhD, the Donald O. Schnuck Family Professor of Neurology at Washington University and the director of the university’s NF Center. “We don’t have a good way to predict who will develop tumors or any way to prevent them. But now that we know these brain tumors are caused by exposure to light and neuronal activity, we can start thinking of next-gen prevention strategies. Maybe we can give kids cool sunglasses to wear with filters or lenses to block out certain wavelengths of light, or repurpose drugs that suppress excessive neuronal activity, and protect these kids from developing brain tumors and losing their sight.”

Co-senior author Michelle Monje, MD, PhD, an associate professor of neurology at Stanford Medicine, previously demonstrated that neuronal activity drives the growth of an aggressive form of brain cancer. But it wasn’t clear whether neuronal activity itself sets in motion the process of tumor formation or if it only bolsters the growth of tumors initiated by other processes.

As part of this study, the researchers used mice with mutations in their Nf1 gene. Such mice start developing low-grade tumors of their optic nerves around 9 weeks of age, and virtually all have tumors by 12 weeks to 16 weeks old. Since the neurons in the optic nerve become active when exposed to light, the researchers investigated whether they could reduce neuronal activity — and, thereby, tumor formation — simply by keeping the mice away from light. They raised mice from age 9 weeks to 16 weeks in the dark and then checked for tumors.

“The results were so striking. Mice raised in the dark simply did not develop tumors, while all the mice raised in the light did, despite their identical genetic predisposition to develop optic nerve tumors,” Monje said. “While we had previously found that neuronal activity is an important regulator of glioma growth, these findings showed how crucial neuronal activity can be for tumor formation.”

Further experiments verified the crucial role of light exposure and narrowed down the critical window to age 6 weeks to 12 weeks. None of the mice reared in the dark during that time frame developed tumors by 24 weeks of age. Putting mice older than 12 weeks, when the tumors already had formed, into darkness slowed tumor growth but did not shrink them.

First author Pan Yuan, PhD, who first worked with Gutmann at Washington University and is now a postdoctoral researcher with Monje, showed that the link between light and tumors requires a protein called neuroligin 3. When their optic nerves are stimulated, mice with Nf1 mutations release abnormally high levels of neuroligin 3. Blocking the protein with a drug or genetically modifying mice to eliminate the neuroligin 3 gene resulted in fewer and smaller tumors.

Moreover, brain tumors from people are also high in neuroligin 3, which suggests the possibility of targeting the protein as a treatment for brain tumors. The researchers analyzed tissue samples from 19 people with low-grade brain tumors and found high levels of neuroligin 3, regardless of whether they arose in children with NF1 or not.

“All of this is teaching us that we may have ignored one really important cell type in nervous system cancers: the neuron,” Gutmann said. “As neurologists, we have been treating overactive neurons for decades with drugs. One of the directions our laboratories are pursuing is repurposing some of those drugs to see if we can shut off unwanted activity, maybe just for a short developmental period, and prevent brain tumors from forming. And there are other points at which we could intervene as well: by limiting light exposure, by targeting neuroligin 3 or inhibiting some other step in the pathway. It has really opened our eyes.”

Pan Y, Hysinger JD, Barron T, Schindler NF, Cobb O, Guo X, Yalçın B, Anastasaki C, Mulinyawe SB, Ponnuswami A, Scheaffer S, Ma Y, Chang K-C, Xia X, Toonen JA, Lennon JJ, Gibson EM, Huguenard J, Liau LM, Goldberg JL, Monje M, Gutmann DH. NF1 mutation drives neuronal activity-dependent optic glioma initiation. Nature. May 26, 2021.  DOI: 10.1038/s41586-021-03580-6

This work was supported by the Department of Defense, grant numbers W81XWH-15-1-0131 and W81XWH-19-1-0260; the National Institute of Neurological Disorders and Stroke, grant numbers R01NS092597 and R35NS07211-01; the National Institutes of Health (NIH) Director’s Pioneer Award, grant number DP1NS111132; the National Cancer Institute, grant number P50CA165962; the National Eye Institute, grant numbers P30EY026877 and F32EY029137; Brantley’s Project supported by Ian’s Friends Foundation; the Gilbert Family Foundation; Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation; Cancer Research UK; Unravel Pediatric Cancer; McKenna Claire Foundation; Kyle O’Connell Foundation; Virginia and D. K. Ludwig Fund for Cancer Research; Waxman Family Research Fund; Stanford Maternal and Child Health Research Institute; Stanford Bio-X Institute; Will Irwin Research Fund; Research to Prevent Blindness Inc.; and Alex’s Lemonade Stand Foundation.

Washington University School of Medicine’s 1,500 faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Children’s hospitals. The School of Medicine is a leader in medical research, teaching and patient care, consistently ranking among the top medical schools in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Children’s hospitals, the School of Medicine is linked to BJC HealthCare.

Tamara covers infectious diseases, molecular microbiology, neurology, neuroscience, surgery, the Institute for Informatics, the Division of Physician-Scientists and the MSTP program. She holds a double bachelor's degree in molecular biophysics & biochemistry and in sociology from Yale University, a master's in public health from the University of California, Berkeley, and a PhD in biomedical science from the University of California, San Diego. She joined WashU Medicine Marketing & Communications in 2016. She has received three Robert G. Fenley writing awards from the American Association of Medical Colleges: a bronze in 2020 for "Mind’s quality control center found in long-ignored brain area," a silver in 2022 for "Mice with hallucination-like behaviors reveal insight into psychotic illness," and a bronze in 2023 for "Race of people given Alzheimer’s blood tests may affect interpretation of results." Since January of 2024, Tamara has been writing under the name Tamara Schneider.